News Sentiment

RCUS sentiment intelligence

Arcus Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 55 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 27.37 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-5.4% over one week, +12.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Arcus Biosciences to Discuss Cancer and Autoimmune Pipeline Aug. 5

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -5.4% Price reacting lower
Trend fit Trend active 12.6% over four weeks
Fair value 64.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 29
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 11
Investing.com 4
TradingView 4
simplywall.st 4
MT Newswires 3
Benzinga 2
Investing.com Canada 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 15
Analyst action 4
Deals and strategy 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-55 of 55
Stock Titan Direct company coverage

Arcus Biosciences (RCUS) president sells 31K shares under 10b5-1 plan

Arcus Biosciences president Juan C. Jaen, through a trust, sold 31,431 shares of common stock between June 22-24, 2026, under a pre-arranged Rule 10b5-1 trading plan. The shares were sold at weighted average prices ranging from $27.03 to $29.66. Following these transactions, Jaen

Tone
Negative 38/100
Event
Market update
Published
24 Jun 2026 22:09
Source
Stock Titan
Investing.com Direct company coverage

Arcus Biosciences president sells $877,501 in company stock

Juan C. Jaen, President of Arcus Biosciences, Inc. (NASDAQ:RCUS), sold 31,431 shares of company stock for approximately $877,501 through a Rule 10b5-1 trading plan. The sales occurred between June 22 and June 24, 2026, with prices ranging from $27.0313 to $29.6595 per share. Thes

Tone
Negative 36/100
Event
Market update
Published
24 Jun 2026 22:09
Source
Investing.com